BriaCell Enhances Patient Access to Pivotal Phase 3 Trial
Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven are adding 30 satellite locations to enroll patients in BriaCell Therapeutics Corp.’s pivotal Phase 3 study. This expansion reflects the company's commitment to providing innovative cancer treatment options.
Active Clinical Sites Across Multiple States
BriaCell’s Phase 3 study currently encompasses 58 active clinical sites across 15 states. Notable sites include Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, and several others that form the backbone of this significant clinical trial. The extensive reach allows for a diverse patient pool, enhancing the study's representativeness and potential impact.
Clinical Investigation Underway
BriaCell, a clinical-stage biotechnology firm focused on developing immunotherapies, is at the forefront of transforming cancer care. Their pivotal Phase 3 clinical study evaluates BriaCell's lead clinical candidate, Bria-IMT™, used in combination with immune checkpoint inhibitors against physician's choice in patients with advanced metastatic breast cancer (Bria-ABC). This significant endeavor aims to provide new hope to patients facing metastatic breast cancer.
Growing Interest in Clinical Trials
“Clinical investigator interest in our Phase 3 study has exceeded our expectations, significantly expanding patient access to our treatment,” commented Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. This robust engagement underscores the urgent need for effective therapies in metastatic breast cancer and highlights the dedication of BriaCell’s clinical partners to advancing patient care.
Assessing the Outcomes
The study's interim data will be assessed once 144 patient events occur, focusing on overall survival comparisons between patients treated with the Bria-IMT combination regimen and those receiving physician's choice. Positive outcomes in this Phase 3 trial could pave the way for full approval and marketing of Bria-IMT to benefit patients in the metastatic breast cancer community.
Recent Developments and Future Expectations
Recently, BriaCell mentioned exciting updates regarding Phase 2 survival data in a similar patient group, suggesting promising results with the Bria-IMT combination regimen. Furthermore, Bria-IMT has received FDA Fast Track designation, which may expedite its pathway to market, further enhancing treatment options for patients.
About BriaCell Therapeutics Corp.
BriaCell is dedicated to pioneering clinical-stage biotechnology, aiming to revolutionize cancer treatment through innovative immunotherapies. For more information about their initiatives and ongoing studies, visit their official site. The company is prepared to share updates and further developments as their research progresses.
Frequently Asked Questions
What is the focus of BriaCell's Phase 3 clinical trial?
The study focuses on evaluating Bria-IMT in combination with immune checkpoint inhibitors for patients with advanced metastatic breast cancer.
How many clinical sites are involved in BriaCell's study?
Currently, there are 58 active clinical sites across 15 states involved in the study.
What are the expected outcomes of the Phase 3 study?
The study aims to demonstrate enhanced overall survival rates in patients receiving Bria-IMT compared to standard physician's choice treatment.
What is Bria-IMT's current regulatory status?
Bria-IMT has received FDA Fast Track designation, accelerating its review process for potential treatments.
How can one learn more about BriaCell's ongoing research?
More information is available on BriaCell's official website, where updates and results from their ongoing studies will be shared.
